Cell death mechanisms triggered by monoclonal antibodies against CD99 in Ewing sarcoma: Cross-talk between MDM2, IGF-1R and Ras/MAPK by Terracciano, Mario
Alma Mater Studiorum – Università di Bologna 
 
DOTTORATO DI RICERCA IN 
 
Biologia Cellulare e Molecolare 
 
 
Ciclo XXVI 
 
 
Settore Concorsuale di afferenza:  05/E1 
Settore Scientifico disciplinare:  Bio/12 
 
 
TITOLO TESI 
 
CELL DEATH MECHANISMS TRIGGERED BY MONOCLONAL ANTIBODIES 
AGAINST CD99 IN EWING SARCOMA: CROSS-TALK BETWEEN MDM2, IGF-1R 
AND RAS/MAPK 
 
Presentata da: Terracciano Mario 
 
Coordinatore Dottorato                                        Relatore 
Chiar.mo Prof. Vincenzo Scarlato                           Chiar.ma Prof.ssa Michela Rugolo 
 
 
                                                                                                                     Correlatore 
            Chiar.ma Prof.ssa Katia Scotlandi 
 
 
Esame finale anno  2014 
  
 
 
 
 
 
 
 
 
 
INDEX 
 
INTRODUCTION………………………………….....................................................2 
1. BONE SARCOMAS…………………………………………………………...2 
2. EWING SARCOMA…………………………………………………………...3 
2.1 Classification……………………………………………………………….3 
2.2 Epidemiology and risk factors……………………………………………...3 
2.3 Localization and histopathology…………………………………………...4 
2.4 Course and therapies……………………………………………………….5 
2.5 Biology of Ewing sarcoma…………………………………………………6 
3. CD99 ANTIGEN……………………………………………………………….9 
3.1 MIC2 gene and CD99 protein……………………………………………...9 
3.2 CD99 expression in normal and tumoral tissues………………………….10 
3.3 CD99 function…………………………………………………………….11 
4. CELL DEATH MECHANISMS……………………………………………...12 
4.1 Apoptosis and autophagy: the main types of programmed cell death…….14 
4.2 Macropinocytosis: an endocytic pathway leading to cell death…………..17 
5. IGF SYSTEM…………………………………………………………………19 
5.1 IGF-1 receptor (IGF-1R) and its molecular signaling…………………….20 
5.2 Ras proteins: structure and function………………………………………22 
5.3 IGF system and cell death: a “paradoxical” role of Ras-MAPK  
pathway…………………………………………………………………...23 
PRELIMINARY DATA AND AIM OF THE STUDY……………………………..24 
MATERIALS AND METHODS……………………………………………………28 
RESULTS……………………………………………………………………………34 
1. IGF-1R/MDM2 relationship in ES……………………………………………34 
2. IGF-1R modulations following 0662 mAb treatments………………………..34 
3. CD99 internalization after its recruitment by 0662 mAb……………………..36 
4. CD99 stability…………………………………………………………………38 
5. Role of lysosomes and endosomes in CD99 internalization process…………40 
6. CD99 internalizes both in a clathrin- and caveolin-1-dependent  
manner………………………………………………………………………...42 
7. CD99 and IGF-1R interaction upon 0662 treatment………………………….44 
8. IGF-1R is not degraded by 0662 mAb treatments…………………………….45 
9. Ras-MAPK signaling is activated in response to treatment…………………..48 
10. Cytoplasm vacuolization during 0662 mAb-induced cell death:  
autophagy hypothesis…………………………………………………………51 
11. Ras has an active role in the observed cell death…………………………….53 
12. Mesenchymal stem cells are resistant to 0662 mAb-induced cell  
death…………………………………………………………………………..55 
13. EWS/FLI1 favors the delivering of the CD99-induced cell death  
message……………………………………………………………………….57 
DISCUSSION………………………………………………………………………..59 
REFERENCES………………………………………………………………………64
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
INTRODUCTION 
 
 
1. BONE SARCOMAS 
Bone sarcomas represent an heterogeneous class of malignant tumors of different 
connective tissues like bones, muscles and cartilage. Global incidence is around 5 
new cases/100000 inhabitants/year, in particular 3000 new cases/year are reported in 
Great Britain and Italy and about 12000 new cases in USA. This incidence is 
considered 1/5-1/6 of all sarcomas, with osteosarcomas the most frequent (0.2 new 
cases/100000 inhabitants/year) followed by the Ewing family tumors with an 
incidence considered one-half in comparison to osteosarcomas. In the past years the 
great heterogeneity of sarcomas made diagnoses complicated and targeted therapeutic 
regimes very difficult to be performed; recently, the development of much more 
accurated metodologies allowed to get a molecular profile – based classification that 
divides sarcomas into two big groups: the first one, which includes alveolar 
rhabdomyosarcoma, synovial sarcoma and Ewing Sarcoma, is characterized by a 
simple cariotype with rare chromosomal rearrangements; the second one, comprising 
osteosarcoma and chondrosarcoma, is associated to a complex cariotype with 
numerous genetic alterations. These alterations involve oncosuppressor genes, like 
p53 and Rb, which can lead to aneuploidy or chromosomal aberrations of different 
nature, while the ones with simple cariotype are usually characterized by specific 
chromosomal traslocations able to generate chimeric proteins with deregulated 
activity. Frequently the mutated genes code for transcription factors or signal 
molecules involved in proliferation mechanisms like growth factors and/or their 
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receptors and, following mutations, they show crucial alterations of regulatory or 
functional motives like DNA binding domains (1). 
2. EWING SARCOMA 
 
 
2.1 Classification 
Ewing sarcoma (ES) is a very rare and aggressive bone tumor of mesenchymal origin 
(2) described for the first time by James Ewing as a “diffuse endothelioma of bone” 
and later as an “endothelial myeloma of bone”. Because of its highly undifferentiated 
small round cell phenotype, for many years it has been considered mainly an 
histologic diagnosis of exclusion. Nowadays, based on the identification of a 
common genetic lesion, a similar clinical behavior and response to treatment, the 
World Health Organization considers this type of tumor, Askin tumors, peripheral 
primitive neuroectodermal tumor (PNET) and extraosseous ES belonging to the 
Ewing sarcoma family tumors (ESFT)(3).  
 
2.2 Epidemiology and risk factors 
ES is the second most common bone tumor after osteosarcoma, it usually strikes 
children and young adults with a peak of incidence between 10 and 20 years of age(4) 
and with a slight prevalence of males than females (1,5:1). Moreover, for unknown 
reasons, Ewing tumors occur most often in whites (either non-Hispanic or Hispanic), 
they are less common among Asian Americans and are extremely rare among African 
Americans. Despite the plethora of data reporting neuroectodermic and stomach 
cancers in families of patients with ES(5), there are no evidences highlighting an 
association between this type of tumor and congenital or family syndrome, while it 
seems to arise as a second tumor in patients previously subjected to radiotherapy, 
although with a lesser extent if compared to osteosarcoma. Lifestyle-related risk 
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factors such as body weight, physical activity, diet, and tobacco use play a major role 
in many adult cancers, but they usually take many years to influence cancer risk, and 
they are not thought to be critical in childhood cancers, including Ewing tumors, for 
whom risk factors are still obscure. 
 
2.3 Localization and histopathology 
The tumor onset may affect flat, short or long bones and it is very rare in the skull. 
The most common localization in the appendicular skeleton is the femur, followed by 
the tibia, humerus, fibula and forearm bones, while in the trunk the pelvis is the most 
frequent site of occurrence, followed by vertebrae and sacrum, scapula, ribs and 
clavicle.  
 
                           
                                Figure 1. Ewing sarcoma localizations (4) 
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Microscopically this cancer is characterized by sheets of small rounded cells closely 
packed, without matrix and rich in glycogen: the cytoplasm is scarce, pale, granular 
and with poorly defined limits; nuclei, on the other hand, present a distinct nuclear 
membrane and they represent the bigger part of the cell.   
 
                    
                      Figure 2.  Histology of Ewing sarcoma/PNET (4) 
 
2.4 Course and therapies 
This type of sarcoma usually displays an aggressive growth with a multiple 
metastatic spread to the lungs, skeleton, lymph nodes and brain, a feature that used to 
make the long-term survival less than 10% before the employment of chemotherapy. 
Nowadays, thanks to multimodal treatments, this percentage increased, making a 5-
years survival possible without any recurrence in almost 60% of cases; nevertheless, 
if metastases are present at the time of diagnosis (20% of cases), the survival 
possibilities decrease dramatically to 20%. ES is sensitive to chemotherapy and 
radiotherapy, but surgery plays a fundamental role in treatment of the primary tumor, 
since it represents the best way to control the neoplasia locally and, in some cases, it 
allows to avoid radiotherapy. The preferred therapeutic approch includes 
chemotherapy given pre- and post-operatively, surgery (whenever feasible) and 
radiotherapy (together with surgery or as an alternative). The most effective drugs are 
cyclophosphamide, ifosfamide, adriamycin, vincristin, actinomycin D and etoposide; 
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multicentric clinical studies demonstrated a higher efficacy for the association of 4 
drugs (vincristin, cyclophosphamide, adriamycin and actinomycin D) if compared to 
an association of 3 drugs or to the utilization of the single drugs alone. Patients with 
metastases at the time of diagnosis treated with the same therapeutic regimen utilized 
for patients having a localized tumor showed a worst prognosis. For these cases, 
promising results have been reached using a much more aggressive chemotherapy, 
with increased doses and  the time between cycles of treatment reduced, followed by 
a bone marrow transplantation with a reinfusion of peripheral stem cells. Bone 
sarcomas are high grade tumors with a devastating tendency to metastatize; 
introduction of multidrug chemotherapy improved prognosis but the price is long-
lasting treatments with very high toxicity and side effects. In addition, despite the 
plethora of recently developed new drugs, patients with metastasis and recurrent 
diseases still have a very poor prognosis due to the lack of effective novel therapies 
against these types of tumors. Further improvements obviously require advances in 
the biological and molecular understanding of these cancers. 
 
 
2.5 Biology of Ewing sarcoma 
Routinely, for ES diagnosis, in addition to the utilization of histochemical and 
immunohistochemical reactions to test different biological markers expression (Table 
1), it is common the employment of electronic microscopy, cytogenetics and 
molecular biology techniques to identify the two main markers of Ewing sarcoma: 
the membrane glycoprotein p30/32MIC2, also known as CD99, and the chromosomal 
traslocation responsible for the generation of a chimeric protein, EWS-Ets, obtained 
as a result from the fusion of N-terminal portion of EWS protein to the C-terminal 
portion of a member of Ets family of trascription factors (2). 
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MARKERS  IMMUNOHISTOCHEMISTRY 
  VIM + 
 CD99 + 
 Caveolina-1 + 
 Fli1 + 
 CAM 5.2 +/- 
 S100 +/- 
 LAC - 
 TdT - 
 
 
  Table 1. Markers routinely used with immunohistochemistry for ESFT diagnosis. 
 
 
EWS gene is a member of TET transcription factors family, characterized by the 
presence of an 87 amminoacids region (RRM/RNP-CS) able to promote the RNA 
binding, and a glutammine-rich N-terminal portion involved in the fusion process to 
EST genes in ESFT tumors. EWS protein function is still poorly defined, even if it 
seems to be involved in trascription mechanisms since it was seen to be associated to 
RNA-polimerase subunits and products. Protein members of Ets family are 
transcription factors whose role can be to activate or downregulate the transcription, 
depending on their interaction with DNA and/or other regulatory proteins. DNA 
binding domain of Ets proteins is part of the chimeric product EWS-Ets, causing its 
aberrant trascriptional activity.   
The traslocation t(11;22)(q24;q12) is present in almost 90% of ES cases; it causes the 
formation of EWS-FLI1 chimeric product, which is the main patognomonic alteration 
of ES, and it is characterized by binding of exon 7 of EWS gene to exon 5 (fusion 
type II) or 6 (fusion type I) of FLI1 gene (Figure 3). The chromosomal traslocation 
t(21;22)(q22;q12) responsible of EWS-ERG transcript generation is present in around 
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5% of the cases, while other chromosomal traslocations are much more rare (Table 
2).  
 
    
                         Figure 3. Different types of EWS/Fli-1 chimera (6) 
 
 
TRASLOCATION GENES  FREQUENCY 
t(11;22)(q24;q12) EWS-FLI1 90-95% 
t(21;22)(q22;q12) EWS-ERG 5-10% 
t(2;22)(q33;q12) EWS-FEV Rare 
t(7;22)(q22;q12) EWS-ETV1 Rare 
t(17;22)(q12;q12) EWS-E1AF Rare 
t(2;16) FUS-FEV Rare 
t(21;16) FUS-ERG Rare 
 
Table 2. Genetic rearrangements typically involved in ESFT 
 
 
EWS-FLI1 protein activity is necessary not only for cell transformation, as 
demonstrated by its forced expression in immortalized murine NIH3T3 fibroblasts 
(7), but also for the maintenance of the disease: silencing EWS-FLI1 leads to a 
 9 
decrease in tumoral growth in vivo and in vitro(8, 9). Besides, numerous genes 
involved in the regulation of proliferation and tumorigenicity are also EWS-FLI1 
specific targets: E2-C, among these, regulates stromelysin, a metallo-protease 
involved in migration and invasion processes, and C-MYC, a transcription factor 
known to have a role in proliferation and apoptosis. However, effects of EWS-FLI1 
expression are strongly dependent on cellular background; critical factors in the 
permissive background are largely unknown, but may include the presence of an 
intact IGF pathway as well as of CD99, both of them very attractive from a 
therapeutic point of view since the first one is known to be upregulated through an 
autocrine activation in most of ES cases, and the second one is a membrane 
glycoprotein highly expressed in this type of tumor, a feature that makes it also a 
good diagnostic marker for ES.  
 
 
3. CD99 ANTIGEN 
 
 
3.1 MIC2 gene and CD99 protein  
The membrane glycoprotein CD99 has been described for the first time in 1979 as an 
antigen particularly expressed in Acute Limphoblastic Leukemia cells, being 
recognised by 12E7 monoclonal antibody (10). 
It is coded by MIC2, a 50 kb gene mapping in the pseudo-autosomic region of both 
sexual chromosomes, X (Xp22.33-Xpter) and Y (Yp11-Ypter). Like all genes 
mapping in this region, MIC2 is characterized by interesting properties: the locus 
present on X chromosome does not undergo lyonization, allowing an equal 
distribution of MIC2 in males and females; besides, it does not follow the rules of 
sex-linked inheritance, and it segregates like autosomic alleles (11).  
Particularly, MIC2 codes for two protein isoforms, resulting from an alternative 
splicing of the primary transcript, known as CD99 type I or wild type and CD99 type 
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II. Comparative gene sequence analyses revealed that cDNA of CD99 type II  has a 
18bp insert between the exon 8 and the exon 9 which is not present in the other 
isoform. Albeit its larger size, it codes for a truncated form of protein, since the 18bp 
insert introduces an in-frame stop codon responsible for the production of a 160 
amminoacids instead of 185. Moreover, biochemical studies showed that CD99 
undergoes post-translational modifications, like O-glycosylation,  causing a reduction 
in protein molecular weight from 32 kDa to 28 kDa and 18 kDa (12). 
To date a CD99 crystal structure is still missing because of its heavy glycosylation, 
but the use of cDNA sequence analyses gave us some indications: CD99 structure is 
made by an O-glycosylated extracellular domain of 100 amminoacids at the N-
terminal portion, a putative hydrofobic transmembrane domain of 25 residues and a 
cytosolic C-terminal portion of 38 amminoacids, making possible the 
immunolocalization of the protein on the cellular surface (13-15). In order to have 
more information regarding the CD99 structure, circular dichroism and NMR 
spectroscopy analyses have been performed; these studies showed that the 
cytoplasmic portion of CD99 is characterized by the presence of an hairpin anchored 
to the plasma membrane with two flexible loops; for this reason, CD99 doesn’t seem 
to have a regular secondary structure. It has been postulated that CD99 could gain a 
rigid conformation only when associated to other partners (16).  
 
 
2.2 CD99 expression in normal and tumoral tissues 
Immunohystochemical studies revealed a ubiquitous distribution of CD99 antigen, 
showing a high expression level in particular in ependymal cells of brain and bone 
marrow, in pancreatic islet, in Sertoli and Leyding cells, and in endothelial cells of 
blood vessels(17). The CD99 function in these cellular contexts is basically unknown, 
on the contrary, its role in hematopoietic system is well documented.  
CD99 is differently expressed according to the cell type and differentiation stage (18-
20). Particularly, CD34+ progenitor cells of bone marrow hematopoietic tissue 
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display high levels of CD99 antigen, which tend to decrease progressively with the 
increasing of differentiation and maturation stage towards type B lymphocyte and 
granulocyte lineage. Regarding CD99 expression in T lymphocyte, it results highly 
expressed in immature thymocytes but its levels decrease proceeding throughout 
differentiation processes (18, 21). 
CD99 resulted expressed also in numerous tumors like acute lymphoblastic leukemia 
(10), embrional rhabdomyosarcoma (17, 22, 23), synovial sarcoma (24), 
mesenchymal condrosarcoma (25, 26) and ependymal tumors (27). However, Ewing 
sarcoma and peripheral neuroectodermic tumors represent the the higher CD99-
expressing neoplasms, making the receptor a reliable diagnostic marker for the cited 
tumors, together with the specific chromosomal traslocations(17, 23). 
 
 
2.3 CD99 function 
Because of its still unknown ligand and the absence of a crystal structure, CD99 
functions in phisiological conditions are barely described. Moreover, the existence of 
two different isoforms makes its role even harder to define. Although present on the 
X chromosome, the CD99 gene does not undergo X inactivation, indicating that the 
molecule should be involved in crucial biological processes. Indeed, CD99 was 
proved to play a role in monocyte diapedesis, T cell adhesion, apoptosis and 
differentiation, HLA exposure and intracellular trafficking (14, 28-31). In pathology, 
CD99 is present on the cell surface of ES, acute lymphoblastic leukemia (ALL), 
thymic tumours, synovial sarcoma, haemangiopericytoma, meningioma and 
malignant glioma, in which it results in higher levels of invasiveness and lower rates 
of survival compared to normal brain (23, 24, 32-34). On the contrary, a lower 
expression of CD99 antigen has been found in Osteosarcoma, a cellular context 
where it plays an oncosuppressor role(35, 36). In ES, high levels of CD99 are 
maintained by EWS-FLI1 (37-41), the oncogenic driver of ES (2), and expression of 
CD99 is required to create the permissive conditions for EWS-FLI1 transformation 
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(40): CD99 knock-down, infact, leads ES cells to a terminal neural differentiated 
phenotype with neurite outgrowth, increased expression of β-III tubulin and neural 
differentiation markers; moreover, it reduces their ability to form tumors and bone 
metastases when xenografted into immunodeficient mice and diminishes their 
tumorigenic characteristics in vitro. On the other hand, triggering of CD99 with 
some, but not all, murine antibodies was found to deliver a massive and rapid cell-
death message both in leukemic and ES cells (42-44) and significantly inhibits tumor 
growth and metastasis formation (45). All together these findings point out a potential 
immunotherapy employment of CD99, since it is easily accessible, it is expressed in 
virtually all cases (46) and it has a role in the pathogenesis of the tumor.  
 
 
4. CELL DEATH MECHANISMS 
 
Cell death can be classified according to its morphological appearance (which may be 
apoptotic, necrotic, autophagic or associated with mitosis), enzymological criteria 
(with and without the involvement of nucleases or of distinct classes of proteases, 
such as caspases, calpains, cathepsins and transglutaminases), functional aspects 
(programmed or accidental, physiological or pathological) or immunological 
characteristics (immunogenic or non-immunogenic)(47). The field of cell death 
research, anyway, has continued its expansion, significant progress has been made 
and new putative cell death modalities have been described since 2005, when the 
Nomenclature Committee on Cell Death (NCCD) formulated the guidelines for the 
definition of the different type of cell deaths (48). 
Dying cells are engaged in a process that is reversible until a first irreversible phase 
or ‘point-of-no-return’ is trespassed. It has been proposed that this step could be 
represented by massive caspase activation (49), loss of ΔΨm (50), complete 
permeabilization of the mitochondrial outer membrane(51) or exposure of 
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phosphatidylserine (PS) residues that emit ‘eat me’ signals for normal neighboring 
cells. However, these parameters are also frequently present in the context of non-
lethal processes and differentiation pathways, making the concept of “point-of-no-
return” hard to be specifically defined.  
In the absence of a clearly defined biochemical event that can be considered as the 
point-of-no-return, the NCCD proposes that a cell should be considered dead when 
any one of the following molecular or morphological criteria is met: (1) the cell has 
lost the integrity of its plasma membrane, as defined by the incorporation of vital 
dyes (e.g., PI) in vitro; (2) the cell, including its nucleus, has undergone complete 
fragmentation into discrete bodies (which are frequently referred to as ‘apoptotic 
bodies’); and/or (3) its corpse (or its fragments) has been engulfed by an adjacent cell 
in vivo (Table 3.)(52). 
 
 
Table 3. Cell death criteria and methods used for its detection(52). 
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4.1 Apoptosis and autophagy: the main types of programmed cell death 
Generally, a cell demise is “programmed” whether is genetically controlled and 
apoptosis and macroautophagy (here referred as autophagy) are universally known as 
the two fundamental types of programmed cell death. 
The term “apoptosis” was coined in 1972 (53), it is a Greek word literally meaning 
“leaves falling from the tree” and represents a set of genetic and biochemical 
pathways essential for development and maintenance of pluricellular organisms. In 
particular, it plays an important role in the organogenesis during embrio 
development, and is involved in regulating cellular homeostasis in adult. 
Alterations of the apoptotic machinery can lead to severe tissue damages and 
pathologies like cancer, autoimmune diseases, cronic diseases like diabetes and 
neurodegenerations. This type of death classically occurs through rounding-up of the 
cell, retraction of pseudopodes,  pyknosis (reduction of cellular volume), chromatin 
condensation, nuclear fragmentation, plasma membrane blebbing (but maintenance of 
its integrity until the final stages of the process) (52). Cytoplasm shrinkage and the 
plasma membrane blebbing represent the final steps of the entire mechanism, ending 
with the formation of vesicles called “apoptotic corps” which, thanks to the presence 
of molecules like phosphatitilserine on their surface, are recognized by specialized 
phagocytes responsible for their degradation. 
Caspases play a fundamental role in the apoptotic process, since their activation mark 
the “point of no return”(54). They represent a cystein-protease family necessary for 
the execution of both pathways of programmed cell death. The first one, called “the 
intrinsic pathway”, is basicly controlled by an interplay between proapoptotic and 
antiapoptotic members of Bcl2 family with the involvement of mithocondria; 
initiators of the pathway include increased intracellular reactive oxygen species, 
radiation-induced DNA damage, exposition to chemotherapeutic agents and the 
deprivation of growth factors. These initiators ultimately lead to increased 
mitochondrial permeability, thereby promoting the release of proapoptotic proteins 
(cytochrome c) from the intermitochondrial membrane space into the cytosol (55, 
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56). Another of these proteins, diablo homologue (SMAC/DIABLO), antagonizes 
cytosolic inhibitors of proapoptosis proteins, thus allowing the activation of caspases 
and hence progression to apoptosis. Activated caspase 9 mobilize caspases 3, 6, and 
7, proteases that herald demolition of the cell by cleaving numerous proteins and 
activating DNases. The extrinsic pathway exploits the binding of members of the 
tumor necrosis factor (TNF) super-family to cell-surface “death receptors,” members 
of the TNF receptor family. Ligation of these receptors initiates the formation of the 
multiprotein death-inducing signaling complex. Aggregation of this complex causes 
conformational changes in its components that trigger the catalytic activity of caspase 
8, a central mediator of apoptosis, and the activation of the same effector caspases of 
the intrinsic pathway (Figura 4).  
 
 
            
        Figure 4. Schematic representation of the apoptotic process (57) 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Autophagy is the process by which cells recycle their own redundant or damaged 
organelles and macromolecular components(58, 59). It is an adaptive response to 
sublethal stress, such as nutrient deprivation, that supplies the cell with metabolites it 
can use for fuel. Nevertheless, if prolonged, can compromise the cell viability and 
become an alternative cell death mechanism, leading the cell to self-digestion.  
It is morphologically defined (especially by transmission electron microscopy) as a 
type of cell death that occurs in the absence of chromatin condensation but 
accompanied by massive autophagic vacuolization of the cytoplasm. In contrast to 
apoptotic cells (whose clearance is ensured by engulfment and lysosomal 
degradation), cells that die with an autophagic morphology have little or no 
association with phagocytes(60, 61). 
This type of programmed cell death is characterized by the sequestration of 
cytoplasmic material within autophagosomes for bulk degradation by lysosomes. 
Autophagosomes, by definition, are two-membraned and contain degenerating 
cytoplasmic organelles or cytosol(62, 63). which allows them to be distinguished by 
transmission electron microscopy from other types of vesicles such as lysosomes or 
apoptotic blebs.  
The autophagic process and machinery are complex, the former consists of five basic 
phases: initiation, elongation, closure, maturation, and degradation (Figure 5). The 
core machinery is constituted by different proteins and each of them has a relevant 
role within the stages of the process: the ATG1/unc-51-like kinase (ULK) complex, 
including ATG13 and the scaffold FIP200, and a second complex comprised of 
Vps34, a class III phosphatidylinositol-3-kinase (PI3K), and ATG6/Beclin1 (64) both 
regulate the initiation phases of autophagy. A third subgroup regulates later steps of 
autophagy, autophagosome elongation, and ex- pansion, and is characterized by two 
ubiquitin-like proteins: LC3 (also known as ATG8/microtubule-associated protein 1 
light chain 3) and ATG12 (65). LC3 becomes inserted into the inner and outer 
membranes of the autophagosome and has been used extensively to monitor 
autophagy. ATG12 is conjugated to ATG5 by the ATG7 and ATG10 proteins and 
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this ATG5– ATG12 conjugate interacts with ATG16L, promoting LC3 lipidation(66, 
67). Autophagosomes, then, fuse with lysosomes, generating autolysosomes, in 
which both the autophagosome inner membrane and its luminal content are degraded 
by acidic lysosomal hydrolases. This catabolic process marks the completion of the 
autophagic pathway.  
 
 
  
                 
           Figure 5. Proteins of the core machinery and autophagic process (68) 
 
 
4.2 Macropinocytosis: an endocytic pathway leading to cell death 
Apoptosis is the best characterized form of programmed cell death. However, during 
the last years nonapoptotic forms of cell death have been studied and recognized as 
playing significant roles during embryonic development, neurodegeneration, and 
cancer regression (69). In these cases, loss of cell viability may occur in a manner 
that is independent of caspase activation. In 1999, Chi et al.(70) reported that ectopic 
expression of activated Ras GTPase, which normally serves to stimulate cell 
proliferation, can trigger nonapoptotic cell death in glioblastoma and gastric 
carcinoma. This was described as autophagic death because the cells developed 
numerous cytoplasmic vacuoles. Later, in 2008, Overmeyer et al.(71) determined that 
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the large vacuoles observed in glioblastoma cells were derived from 
macropinosomes, terming this process “Methuosis” (from the Greek word methuo, 
which means “drink to intoxication”). 
Macropinocytosis is a regulated form of endocytosis that mediates the uptake of 
solute molecules, nutrients and antigens in a clathrin-independent manner. It begins 
with an actin-mediated membrane ruffling of the plasma membrane, then some of the 
lamellipodia on the cell surface  fold back onto themselves and fuse with the basal 
membrane creating large, irregular shaped vesicles termed macropinosomes which 
undergo a maturation process that is slightly different basing on the cellular context 
(Figure 6). 
 
                   
    
                            Figure 6. Pathway of Macropinocytosis (72) 
 
 
This endocytic process has a physiological relevance: being associated with actin-
dependent ruffling of the plasma membrane, this pathway is implicated in cell 
motility and, therefore, in tumor progression and metastasis; its role is also 
documented in the chemotactic response of neutrophils (73), while in the immune 
system, macropinocytosis is means by which cells internalize antigens to be then 
processed and loaded onto MHC molecules(74, 75). Although considerable progress 
has been made in understanding the cell biology of macropinocytosis, there remain 
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many unanswered questions: how do the different regulators of macropinocytosis 
regulate the entire process? Which events are associated with the formation and the 
maturation of macropinocytosis?  
A key difference between clathrin-dependent endocytosis and macropinocytosis is 
that the latter requires actin cytoskeleton reorganisation. This was seen not only in 
Dictyoselium discoideum (76), but also in mouse macrophages (77), therefore, it does 
not surprise that components of signal transduction pathways linking receptor 
stimulation to actin cytoskeleton remodelling are also implicated as regulators of 
macropinocytosis. One such candidate is the Ras oncogene.   
 
 
5. IGF SYSTEM 
 
The role of growth factors in the pathogenesis of neoplasms is well documented, a lot 
of data in literature report a connection between tumors, growth factors and their own 
receptors. Among them, IGF system, being involved in cellular growth and 
proliferation because of its relevance in cell cycle progression from G1 to S phase, 
has been investigated by many research groups all around the world for years, 
disclosing its importance in developing and maintenance of different types of 
cancers. It is composed by several elements: two ligands IGF-1 and IGF-2; three 
membrane receptors IGF-1R, IGF-2R and IR; moreover, there are six proteins able to 
bind IGF ligands with a high affinity, IGF-Binding Proteins (IGFBP-1, -2, -3, -4, -5, -
6), in order to modulate their bioavailability and preventing their degradation . 
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5.1 IGF-1 receptor (IGF-1R) and its molecular signaling 
IGF-1R is a tetramer of 2 alpha and 2 beta chains linked by disulfide bonds; the alpha 
chains contribute to the formation of the ligand-binding domain, while the beta chain 
carries the kinase domain (78). Ligand binding (IGF-1 with a high affinity and IGF-2 
with a lower affinity) activates the receptor kinase, leading to receptor 
autophosphorylation on tyrosines residues (Tyr-1165, Tyr-1161 and Tyr-1166) (79) 
and consequent phosphorylation of multiple substrates, that function as signaling 
adaptor proteins: the insulin-receptor substrates (IRSs proteins), Shc and 14-3-3 
proteins. The IRS1 and Shc signaling pathways represent the main signal trasmission 
routes regulated by IGF-1R, leading, respectively, to the induction of the PI3K-
AKT/PKB pathway and the Ras-MAPK pathway (Figure 7). The recruitment of IRSs 
proteins on IGF-1R causes the phosphorylation of specific residues which act as 
docking sites for proteins SH2-containing domains, like PI3-K (phosphoinositide-3-
kinase). In particular, they bind PI3-K regulatory subunit, p85, favoring the 
traslocation of the catalitic subunit p110 on the plasma membrane, where, in turn, 
phosphorylates the phosphatidylinositole-(4,5)-biphosphate (PIP2) to 
phosphatidylinositole-(4,5)-triphosphate (PIP3). This event leads, ultimately, to the 
recruitment of B kinase protein (AKT) on the plasma membrane, with its subsequent 
conformational change and activation. AKT activation causes the induction of 
different proteins whose effect are the increase in protein synthesis mediated by 
mTOR on one hand, and on the other hand the apoptosis inhibition through the 
inhibitory phosphorylation of pro-apoptotic factors such as Bad. Shc activation 
stimulates, on the contrary, the Ras-MAPK pathway: Ras is a small membrane 
GTPase protein considered inactive if bound to GDP; following the receptor 
autophosphorylation, Sos factor (Son-of-sevenless) mediates the Ras activation 
catalizing its binding with GTP. The association between Sos and its substrate is 
controlled by the adaptor protein Grb2, which is able to bind specific 
phosphotyrosines on the receptor and, in turn, is activated by interacting with 
Shc(80). Once in the active form, Ras translocates to the plasma membrane and 
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induces the activation of the serine/treonine kinase Raf; the latter is able to positively 
modulate the phosphorylation of a series of tyrosine-kinase proteins belonging to the 
MAP kinase family (Mitogen Activate Protein Kinase). All these events cause the 
Erk1/2 activation (Extracellular signal-regulated kinase), through the double 
phosphorylation borne by tyrosines and treonines residues. Erk, then, may 
phosphorylates different targets, both at the membrane or at the cytoplasmic level, 
besides, is also able to translocate into the nucleus and regulate the expression of 
specific transcription factors, such as Fos and Elk1.  
 
 
   
 
  Figure 7. Key regulators of IGF-1R signal pathway (81) 
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5.2 Ras proteins: structure and function 
Mammals encode three ras genes, H-ras, K-ras, and N-ras, whose protein product is 
present in every cell type and tissue  although the expression pattern varies depending 
on the organ and the stage of development (82). 
The product encoded by the ras genes is a protein of 188 amino acids (189 in KRasB) 
of approximately 21 kDa.  The three isoforms show an homology in their first 164 
amino acids, while they differ completely in the so called “heterogeneous region”, a 
segment of the carboxy-terminal region made by residues 165-185 (83). Ras 
biological activity resides in what has been termed the effector domain (amino acids 
32 – 40) by means of which it binds to the different effector molecules (84).  
Ras proteins exert their function switching from an inactive state, in which they are 
bound to guanine dinucleotides (GDPs), to an active state, bound to guanine 
trinucleotides (GTPs). This mechanism is tightly regulated by two types of regulatory 
proteins: guanine nucleotide exchange factors (GEFs), able to catalyze the GDP/GTP 
exchange, and GTPase- activating proteins (GAPs), which enhance the intrinsic 
capacity of Ras to hydrolyze GTP into GDP, thereby returning Ras to the inactive 
state (83, 85). Structural differences between the active and inactive states are 
apparently restricted to the switch I (residues 30 – 38) and switch II (residues 60 – 
76) regions (86). The switch I region comprises the main binding site for effector 
molecules and GAPs, while the switch II region is involved in part in the interaction 
with GEF regions(84, 87, 88).  
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5.3 IGF system and cell death: a “paradoxical” role of Ras-MAPK 
pathway 
Despite the foregoing, an increasing number of evidence demonstrate also a 
“paradoxical” role for IGF-1R and its effectors Ras-MAPK. In particular IGF-1R, 
among others, has been shown to be responsible of a nonapoptotic form of cell death 
in 293T cells called “paraptosis”, associated with a massive cytoplasmic 
vacuolization(90, 91); moreover, IGF-1R and IR have been found implicated in 
apoptotic mechanisms in primary cultured MEFs and in brown preadipocytes wheter 
the two receptors were both present and unoccupied (92). Despite its well described 
role in tumorigenesis as a pro-survival/proliferation factor, increasing evidence 
indicates that RAS is able to switch cell fate toward death in specific cellular 
contexts, such as in normal primary cells  and in cancer cells under certain 
conditions(89, 93). Its activation can induce non-apoptotic cell death in 
neuroblastoma through a classical autophagic process (94, 95), while in glioblastoma 
RAS-regulated death occurs through Rac-dependent pathways hyperstimulating 
macropinocytosis (71). Depending on the duration, the magnitude and its subcellular 
localization, ERK activation controls various cell responses, such as proliferation, 
migration and differentiation but also death (96). A constitutive activation of ERK by 
active Raf (97), and IGF-I receptor(91) has been demonstrated to induce a form of 
cell death correlated with extensive cell rounding and the formation of cytoplasmic 
macrovacuoles, a morphology not related to an apoptotic cell death but that resembles 
rather an autophagic-like death or paraptosis. Moreover, depending on the cell type 
and the nature of the injury, ERK activation has been found associated both with the 
intrinsic apoptotic pathway(98-100) and with the extrinsic one (101-103). Notably, 
ERK promotes p53 stability and activity, a tumor suppressor involved also in 
apoptotic processes, by phosphorylating its serine 15 residue (104-106), and by 
inhibiting MDM2 phosphorylation on its serine 166 residue, which is associated with 
its ubiquitin ligase activity toward p53(107). 
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Preliminary data and aim of the study 
 
Preliminary data demonstrate that CD99 triggering by monoclonal antibodies leads to 
a massive and rapid death of Ewing sarcoma cell lines in vitro and in vivo, through a 
non canonical caspase-independent mechanism (44). The employment of the anti-
CD99 0662 antibody promotes, indeed, the phosphatidylserine exposure on the outer 
leaflet of the plasma membrane, a typical marker of the apoptotic process; 
nevertheless, the cell death occurs without caspases involvement or PARP clivage 
(Figure 9). 
 
 
 
 
Figure 9. CD99-induced death occurs in a caspase-independent manner. (a). FACS analysis of 
Annexin V/PI in different ES cell lines following 0662 mAb treatments in presence or not of the 
caspase inhibitor zVAD-fmk. (b) Western blot analysis of caspase/PARP clivage in the ES cell line 
6647(44). 
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The observed cell death mechanism is promoted by a reactivation of p53 through the 
phosphorylation on its serine 15 residue, an event that makes this trascription factor 
able to traslocate into the nucleus, thus inducing the expression of some downstream 
effectors such as Bax and p21, the first one a pro-apoptotic factor and the second one 
a cell cycle inhibitor (Figure 10). 
 
 
 
 
 
 
Figure 10. p53 phosphorylation and induction of its effectors p21 and Bax after 0662 mAb 
treatments in 6647 and LAP35 ES cell lines. 
 
 
The fundamental role of p53 has been confirmed with loss of function experiments:  
exploiting siRNA oligonucleotides, p53 has been transiently knocked-down in 6647 
and LAP35 cell lines, causing a reduction of the entire death mechanism if compared 
to the parental untransfected or scramble cell line, further suggesting that CD99-
induced death is p53-dependent (Figure 11). 
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Figure 11. p53 partecipates actively to the CD99-induced cell death. In the upper panels Annexin 
V-PI analysis is shown, expressed as percentage of live (black), apoptotic (dark grey) or necrotic 
(light grey), in scramble or p53-silenced 6647 or LAP35 cells before and after treatment (30 min) 
with 5µg/mL 0662 MAb. 
 
 
 
Normally, in non-transformed cellular contexts, p53 expression levels are regulated 
by MDM2, an E3 ubiquitin ligase which antagonizes the tumor suppressor by 
sequestering it into the cytoplasm, favouring, then, its ubiquitination and subsequent 
degradation by the proteasome. MDM2 is frequently overexpressed in ES (108), and 
our preliminary data demonstrate that its protein levels decrease in a time- and dose-
dependent manner following 0662 mAb treatments, a reduction caused by a self-
ubiquitination and proteasome degradation (Figure 12), leading, as a result, to the p53 
reactivation previously described.  
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Figure 12. MDM2 expression in ES cell lines. Upper-left panel: whole cell lysates from untreated 
(-) or MAb treated (+) LAP35 cells and whole cell lysates from 6647 cells, untreated or treated with 
increasing concentration of 0662 MAb; right panel: Western blot evaluation of MDM2 (upper 
panel) and ubiquitin (lower panel) on total cell lysates, anti-MDM2 or anti-IgG immunoprecipitates 
from LAP35 cells treated with MG132 alone or plus 0662 MAb. Lower-left panel: Histogram 
depicting 6647 (left) and LAP35 (right) percentage of viable cells (vital cell counting) before and 
after a16 h treatment with 10µg/mL 0662 MAb, alone or in combination with MG132. 
 
 
Besides p53, many studies report that MDM2 serves as a ubiquitin ligase also for the 
IGF-1R(109-111), thereby causing its degradation by the proteasome. On these bases, 
the present PhD project aims to: 
•  Evaluate IGF-1R modulations in response to 0662 mAb treatments in ES cells; 
•  Identify IGF-1R effectors positively or negatively regulated, and figure out 
what is the significance of this modulation; 
•  Dissect the mechanism by means of which CD99 starts its signalling and assess 
its fate when triggered by mAbs ; 
•   Investigate the effects of anti-CD99 mAb treatments in normal cells, in order to 
rule out possible concerns about toxicity related to the employment of these 
antibodies.  
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MATERIALS & METHODS 
 
 
Cell lines and primary cell coltures. 
SK-ES-1, SK-N-MC and RD-ES were obtained from the American Type Culture 
Collection (Rockville, MD, USA). TC71 and 6647 ES cell lines were a generous gift 
from TJ. Triche (Children Hospital, Los Angeles, CA, USA); Peripheral 
neuroectodermal tumor cell line LAP-35 was previously established and 
characterized at the Istituti Ortopedici Rizzoli, Bologna, Italy. The 6647 variant 
6647/CD99low, was previously obtained in our laboratory after a long and continous 
exposure to 0662 mAb as previously described (40). The stably expressing CD99 
U2/CD99wt57 was previously established in our laboratory (35). Murine C3H10T1/2 
cells transfected with EWS/FLI-1(C3H10T1/2 EF) were provided by F. Lecanda 
(University of Navarra, Pamplona, Spain). ES cell lines have been tested for 
mycoplasma contamination (Mycoplasma detection Set, Takara Bio Inc.) and have 
been authenticated by STR PCR analysis. Cells were cultured in IMDM (Gibco), 
supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin and 10% 
inactivated fetal bovine serum (FBS) (Lonza). Bone marrow-derived human 
mesenchimal stem cells were obtained from healthy donors or patients with benign 
bone lesions. After washings, cells were plated in α-MEM (Gibco), supplemented 
with 100 units/ml penicillin, 100 µg/ml streptomycin and 20% inactivated fetal 
bovine serum (FBS) (Lonza). Primary hMSC cell cultures were characterized for 
mesenchymal markers as well as for their differentiative ability and used within 6 in 
vitro passages. 
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Lentiviral infections, transient and stable transfections 
All stable transfections were performed using Calcium Phosphate transfection Kit 
(Invitrogen): LAP35 cells were transfected with pCMV or pCMV-MDM2 and 
maintained in selective medium containing neomycin [250 µg/ml]; 6647 was 
transfected with pBABEpuro-HRasN17, and cells expressing the mutant form of Ras 
were selected with puromycin [500 ng/ml]; U2/CD99 wt57 were derived from the 
osteosarcoma cell line U2-OS transfected with pcDNA3-CD99 and maintained in 
selective medium containing neomycin [500 µg/ml]; C3H10T1/2 EF cells were 
transfected with pcDNA3-CD99 and cultured in medium containing neomycin [500 
µg/ml]; 6647 cells were transiently transfected with pcDNA3/His-Ub by using 
Lipofectamine 2000 (Invitrogen), 48 hours later treatments and nichel-beads pull 
down were performed; pLKO.1 shAtg7-E8 (TET-ON inducible) and pGIPZ sh SCR 
(constitutive) were transfected on HEK293T cells to generate lentiviral supernatant to 
infect ES cell lines. Genetically-modified cells were employed for 0662-mAb 
treatment and subsequent apoptosis assays, cell count or western blot analysis.  
 
0662 mAb treatments 
The anti-CD99 0662 monoclonal antibody (mAb) was produced in the Unite´ 
INSERM 343, Hospital de l’Archet, Nice, France, and cauterized during the Human 
Leukocyte Differentiation Agents International Workshop in 1989 and 1993 (Gelin C 
et al., 1995). Treatments with 0662 mAb were either performed on adherent cells or 
in suspension. Particularly, cells were washed in PBS, and detached from substrate 
with trypsin-EDTA 0.5%, counted and seeded at final concentration of 5X106/mL 
and incubated in IMDM 10% FBS with or w/o 0662 mAb. After the indicated time-
points, control and treated samples were washed in PBS and employed for Annexin-
V/propidium iodide (PI) evaluation (Mebcyto apoptosis Kit, MBL) by flow 
cytometry, trypan blue cell count, cell viability analysis (MTT assay kit, Roche) or 
for protein/RNA extraction. To evaluate the proteasome- and lysosome-mediated 
degradation, treatments have been performed with 0662 alone or together with 
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MG132 [20 µM] and lysosome inhibitor [100 µM], both alone or combined; 
lysosome inhibitor was composed by leupeptin and pepstatin. Unless differently 
specified, all treatments have been carried out with 0662 [3 µg/ml].  Morphological 
alterations were analyzed by electron microscopy. LC3-II positive autophagosomes 
were detected by immunogold staining on ultrathin section by electron microscopy.  
 
Electron microscopy analysis. 
6647 or LAP35 cells treated with 10 µg/mL of 0662 mAb for 30 min were fixed with 
2.5 % glutaraldehyde in 0.1 M cacodilate buffer, pH 7.4, postfixed with 1% OsO4 , 
dehydrated to absolute ethanol and embedded in Epon. For immunogold labeling  
LAP35 cells untreated or exposed to anti-CD99 0662 mAb (10 µg/mL) for 3h were 
fixed with 4 % paraformaldehyde and immunolabeled with anti-LC3B primary 
antibody; a goat anti-rabbit IgG conjugated with 5 nm colloidal gold  particles  was 
used as secondary antibody (GE Healthcare Biosciences, USA). Signal was amplified 
with Silver Enhancer kit (GE healthcare Biosciences). After immunolabeling cell 
monolayers were fixed with 1 % glutaraldehyde in 0.1 M Na-phosphate buffer, 
postfixed with  0.5% OsO4 , dehydrated to absolute ethanol and embedded in Epon. 
Ultrathin sections were stained with uranyl acetate and lead citrate before electron 
microscopy observation with a Zeiss EM109 electron microscope. 
 
Immunofluorescence staining. 
Cells were seeded on poly-D-lysine-coated coverslips (BD Biosciences) and after 24h 
stimulated with anti-CD99 mAb. The stained preparations were observed with a 
confocal microscopy Nikon A1R and/or with a fluorescence microscopy Nikon 
Eclipse 90i or 300 (Nikon); the fluorescence was visualized with a digital imaging 
system using an inverted epifluorescence microscope (Nikon Eclipse 300) with 
63X/1.4 oil objective (Nikon Eclipse Ti-U, Nikon, Japan) and Omega Filter pinkel 
Set XF66-1 triband (Omega Optical Inc., Brattleboro,VT, USA). Images were 
captured with a back-illuminated Photometrics Cascade CCD camera system (Roper 
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Scientific, Tucson, AZ, USA) with 500ms of exposure time and elaborated with 
Metamorph acquisition/analysis software (Universal Imaging Corp., Downingtown, 
PA, USA). After washing in PBS, cells were fixed in 4% paraformaldeyde and 
permeabilized in TritonX-100 0.15%-PBS, blocked in 4% BSA and incubated with 
specific antibodies for immunofluorescence analysis:  anti-CD99 primary antibody 
(Abcam, clone 12E7) + anti-mouse PE; anti-Lamp-1 polyclonal antibody (Santa Cruz 
Biotechnologies) + anti-rabbit FITC (Dako); anti-Lamp-1PE (BD Pharmigen); anti-
Rab4 polyclonal antibody (Thermo Scientific) + anti-rabbit FITC(Dako); anti-Rab11 
(Abcam) + anti-rabbit FITC(Dako); anti-clathrin polyclona antibody (Cell Signaling) 
+ anti-rabbit FITC(Dako); anti-caveolin-1 (BD-transduction labs) + anti-rabbit 
FITC(Dako); anti-IGF-1R (Santa Cruz Biotechnologies, clone C20) + anti-rabbit 
FITC(Dako); anti-IGF1RPE (Pharmigen); anti-Rab5 (Thermo Scientific) + goat anti-
rabbit Dy Light 350 (Thermo scientific). Nuclei were counterstained with Hoechst 
33342.  
 
Western blotting and immunoprecipitation. 
Cells were lysed with Phospho-protein extraction Buffer (Upstate) supplemented with 
protease-phosphatase cocktail inhibitor (Sigma). Proteins of interest were detected 
with specific antibodies: anti-p53 (DO-1) monoclonal antibody (SEROTEC), anti-
ser15-P p53 polyclonal antibody (Cell signaling Technologies), anti-p21 (H-164) 
polyclonal antibody (Santa Cruz Biotechnology), anti-Ub (P4D1) monoclonal 
antibody (Santa Cruz Biotechnology), anti-mdm2 (OP-46) monoclonal antibody 
(Calbiochem) and anti-gapdh (FL-335) polyclonal antibody (Santa Cruz 
Biotechnology), anti-pan RAS (Ab-1) monoclonal antibody (Oncogene), anti-Fli1 (C-
19) rabbit polyclonal antibody (Santa Cruz Biotechnology), anti-ATG7 (2631) 
polyclonal antibody (Cell signaling Technologies), anti IGF-1R (C-20) polyclonal 
antibody (Santa Cruz Biotechnology), anti - ERK (Cell signaling), anti - thr202-
tyr204-pERK (Covance). For immunoprecipitation, 500µg or 900 µg of cell lysates 
were incubated for 16 hours with Protein G-Plus agarose beads (Calbiochem) in the 
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presence of 2µg anti-CD99 (abcam) or 3 µg anti-IGF-1R antibody (Calbiochem). 
Immunoprecipitates and 40 µg total lysates were then resolved on a 10% Tris-HCl 
gel and immunoblotted with specific antibodies. 
 
ELISA assay. 
To determine the CD99 internalization, ELISA assays were performed in 6647 cell 
line: 70000 cells/time-point treatment were seeded in multi 24 plates and mAb treated 
after 24h for the indicated times;  cells were then starved for 3 hours and washed in 
TBS 1X, subsequently they were fixed in 3.7% TBS-paraformaldeyde and blocked in 
1% TBS-BSA. After the incubation with the anti-mouse alkaline phosphatase-
conjugated secondary antibody, the relative substrate (BIO-RAD Cat# 172-1063)  
was added to the cells. The reaction was stopped by adding NaOH 0.4 N, then 
absorbance was read at 405 nm.  
 
Nichel-beads pull down. 
Co-treatments with 0662 [3 µg/ml] and MG132  [20 µM] + lysosome inhibitor [100 
µM] have been performed in 6647 cell lines, then cells were lysed in Buffer A 
(HNTG+MG132/leu/pep + ”complete” cocktail phosphatase inhibitors (Sigma) 
+PMSF+Na3VO4); in parallel, nichel beads (Qiagen) have been washed 3 times in 
PBS and one time in Buffer A, then resuspended in Buffer A and added to each lysate 
previously solubilized in Buffer A (500 µg). After an over-night rotate incubation at 
4°C samples have been washed 3 times in Buffer B (HNTG+Inhibitors+Imidazole 20 
mM pH 8), then Buffer C (HNTG+Inhibitors+Imidazole 250 mM) was added to the 
pellets; the suspensions have been vortexed and spinned, then resuspended in Buffer 
C + laemli buffer, boiled and resolved on a 10% Tris-HCl gel. 
 
Flow cytometry analysis. 
The expression of CD99 was analyzed by indirect immunofluorescence and flow 
cytometry analysis (FACS Calibur, Becton Dickinson): cells were counted and a 
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pellet of 500000 cells was obtained;  then, they have been resuspended using the anti-
CD99 O13 monoclonal antibody (mAb) (Covance), 1: 80 + Goat anti-Mouse IgG 
(H+L) FITC (diluizione 1:100) (Thermo Fisher Scientific Inc). Both incubations were 
stopped by adding serum-free medium and, as a final step, cells have been 
resuspended in PBS-diluited ethidium bromide [1µg/ml], before proceeding to FACS 
analysis. 
 
RNA extraction and Real Time PCR. 
RNAs were extracted using TRIZOL reagent (Life Tecnologies, cat# 15596018). Pre-
designed TaqMan probes were chosen for IGF-1R (Taqman assay # 
Hs00181385_m1) and for GAPDH endogenous control (Taqman assay # 
Hs99999905_m1) (Applied Biosystems). Samples were analyzed using an ABI Prism 
7900 Sequence Detection System (Applied Biosystems, Foster City, CA), according 
to manufacturer's instructions. Expression levels of target genes were normalized to 
that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the relative 
quantification analysis was performed on the basis of the ΔΔCT method. cDNA from 
untreated cells was used as calibrator for the comparative analysis. 
 
Plasmids 
pLKO.1 shAtg7-E8 (TET-ON inducible) and pGIPZ sh SCR (constitutive) were 
kindly provided by Bruno Calabretta, Philadelphia, USA; pCMV or pCMV-MDM2 
were kindly provided by Dr Fabiola Moretti, Rome; pBABE-HRasN17 was kindly 
provided by Dr Kurosaki, Moriguchi, Japan; pcDNA3/His-Ub was kindly provided 
by Dr Andrea Morrione, Philadelphia,PA. 
 
Statistics 
Differences among means were analyzed using 2-tailed Student’s t test. Fisher’s 
exact test was used for frequency data. A P value less than 0.05 was considered 
significant. 
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RESULTS 
 
 
1. IGF-1R/MDM2 relationship in ES 
In order to confirm the well documented role of MDM2 as a negative regulator of 
IGF-1R also in the ES cellular context, we took advantage of a Ewing cell line stably 
expressing WT-MDM2 (LAP35-MDM2) or carrying the pCMV empty vector 
(LAP35-E.V.) to evaluate IGF-1R protein expression. As shown by the western blot 
analysis in Figure 13, LAP35 cells overexpressing MDM2 not only present a marked 
p53 downregulation, but they are characterized also by decreased levels of IGF-1R 
expression. 
 
                              Figure 13. MDM2 downregulates IGF-1R in ES.  
 
 
2. IGF1R modulations following 0662 mAb treatments 
Once highlighted the inverse correlation between the ubiquitin ligase and IGF1R, and 
since preliminary data demonstrated the MDM2 downregulation in response to 0662 
mAb treatments, we proceeded to evaluate IGF-1R modulations following CD99 
triggering by 0662 mAb, both at mRNA and protein level. Real Time PCR and 
Western blot analyses performed, respectively, using cDNAs and lysates from 
LAP35 and 6647 cell lines previously treated with 0662 mAb for different times, 
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revealed a marked induction of the receptor at every time point of the treatment 
(Figure 14). 
 
 
Figure 14. IGF-1R induction following CD99 engagement by 0662 mAb in 6647 and LAP-35. 
Upper panels: Graphs showing results of Real Time PCR; lower panels: western blot analysis 
confirming RT PCR data. All treatments have been carried out for 15-30-60 minutes with 0662 10 
µg/ml. 
 
 
Concomitantly, flow cytometry analysis of IGF-1R carried out on a panel of 0662 
mAb-treated ES cells resulted in a decrease of the receptor expression on the cell 
surface if compared to the respective untreated control; same phenomenon has been 
observed in a ES cell line obtained by continous and long exposure to the 0662 mAb, 
6647CD99low: despite the IGF-1R induction, together with ERK phosphorylation and 
MDM2 downregulation detected by western blot, the expression level of the receptor 
on the plasma membrane was significantly lower than that registered  in 6647 (Figure 
15). 
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Figure 15. Flow cytometry analysis showing the IGF-1R decreased levels on the surface of ES 
cells. Western blot analysis of IGF-1R, p-ERK and MDM2 basal expression in 6647CD99low are 
shown in the lower-right panel.   
 
 
3. CD99 internalization after its recruitment by 0662 mAb 
One of the issues not mentioned in literature and totally unknown was the CD99 fate 
following treatments; to get more insight, we explored the internalization hypothesis 
by using ELISA and immunofluorescence (IF) assays. Taking advantage of 
U2/CD99wt57, an osteosarcoma cell line derived from U2-OS and stably transfected 
with CD99 (Figure 16,left panel), we treated cells for 1h and 3h with 0662 mAb, then 
we proceeded to the receptor immunostaining: untreated U2/CD99wt57 showed 
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CD99 widespread homogeneously throughout the entire cell surface; after 1 hour of 
treatment it began to form aggregates right beneath the plasma membrane, moving 
into the cytoplasm after 3 hours (Figure 16). 
 
    
Figure 16. On the left, CD99 internalization in U2/CD99wt57 treated for 1h and 3h with 0662 
3µg/ml. In the right panel FACS analysis of CD99 expression in 6647, U2-OS and U2/CD99wt57. 
 
 
In parallel, in order to have a quantitative evaluation of CD99 internalization, we 
carried out some ELISA assays in 6647 mAb-treated, concluding that it internalizes 
into the cell in a time-dependent manner (Figure 17). 
 
 38 
 
 
Figure 17. Time-dependent CD99 internalization in 6647 treated for 30’ and 60’ with 0662 3µg/ml. 
 
 
4. CD99 stability 
Once determined that CD99 traslocates into the cytoplasm, it remained to be 
elucidated its stability.  We set up a time-course treatment in 6647 and U2/CD99wt57 
and, as depicted in Figure 18, we found out that CD99 protein levels decreased after 2 
hours of treatment in 6647 and after 4 hours in U2/CD99wt57. The next step has been 
to figure out which mechanism could cause the observed CD99 reduction: to this 
purpose, we transiently transfected 6647 with a plasmid expressing a 6xHis-tagged 
ubiquitin (His-Ub), then I treated cells with 0662 mAb and proteasome/lysosome 
inhibitors at the same time and I subsequently performed a nichel beads pull-down to 
assess wheter CD99 could be ubiquitinated as a consequence of the treatment. Anti-
CD99 western blotting represented in Figure 18 confirmed that CD99 is poly-
ubiquitinated, suggesting that its degradation could be proteasome-mediated. 
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Figure 18. CD99 stability upon 0662 mAb treatments.  (A) Western blots and respective 
densitometric analyses showing CD99 reduction in 6647 and U2/CD99wt57. (B) Nichel beads pull-
down on lysates from 6647 transiently expressing a 6x His-tagged ubiquitin and treated with 0662 
mAb and proteasome + lysosome inhibitors. 
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5. Role of lysosomes and endosomes in CD99 internalization 
process 
 
In order to better define the mechanism by means of which CD99 protein amounts 
underwent the observed reduction, we explored, in parallel, two possible ways: the 
proteasome- and the lysosome-mediated degradation. 6647 have been treated with 
0662 alone or in combination with MG132 (proteasome inhibitor), with lysosome 
inhibitor or both; based on the results shown in Figure 19, CD99 protein expression 
decreased following 2 hours of 0662 treatment alone, while the employment of the 
inhibitors visibly blocked the mAb-induced reduction of CD99. In particular, 
densitometric analysis emphasizes the CD99 rescue by the lysosome inhibitor, which 
seems to be predominant compared to that mediated by MG132. 
 
    
Figure 19. CD99 degradation is inhibited by blocking proteasome and lysosomes.  
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For this reason, I evaluated by confocal microscopy  a colocalization between CD99 
and Lamp-1, the latter considered the main marker of lysosomes, in U2/CD99wt57 
0662-treated for 1 hour, 3 hours and 6 hours in presence of both MG132 and 
lysosome inhibitor. Normally the lysosome degradation is a very late event which 
becomes to be clearly visible after many hours upon a stimulus, in this case the two 
molecules colocalized after only 1 hour, increasing considerably their interaction in 
the other time points, concomitantly with the formation of enormous aggregates 
(Figura 20).   
       
Figure 20. IF (left panel) and confocal microscopy (right panel) images of CD99/Lamp-1 
colocalization upon 1h, 3h and 6h of 0662 treatment in combination with MG132 and lysosome 
inhibitor. The interaction is depicted as yellow dots, which become bigger in the last two time-
points because of the employment of the inhibitors that favour the CD99 accumulation.  
 
 
As a further confirm of its degradation, CD99 was not found to colocalize with 
Rab11, a late endosome marker implicated in recycling mechanisms, after 30 and 90 
minutes of 0662 treatment. Notably, the internalization process resulted to be 
endosome-mediated, since CD99 was found associated to Rab4, an early endosome 
marker involved also in the biogenesis of endosomes, particularly after 30 minutes of 
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treatment (Figura 21). 
 
 
    
Figure 21. Evaluation of CD99/Rab11 (upper panel) and CD99/Rab4 (lower panel) colocalizations 
by IF assays upon 30 and 90 minutes of 0662 treatment. The interaction (yellow areas) is detected 
for CD99/Rab4, but not for CD99/Rab11. 
 
 
6. CD99 internalizes both in a clathrin- and caveolin-1-dependent 
manner 
After having demostrated that CD99 undergoes an internalization process leading, as 
a final step, to its degradation by lysosomes, we examined the beginning of the entire 
process, in order to identify the endocytosis route mainly involved. The latter can 
occur through two different pathways: the clathrin-dependent and the clathrin-
independent endocytic pathways; the first one requires the formation of clathrin-
coated vescicles, while the second one takes place through the formation of the 
caveolae, invaginations of plasma membrane whose main component is caveolin-1. 
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We performed IF assays in U2/CD99wt57 0662-treated for 10, 30 and 60 minutes to 
test the eventual colocalization between CD99 and clathrin or caveolin-1, and, 
surprisingly, we found out that both pathways partecipated in the endocytosis process 
(Figura 22).  
  
       
Figure 22. Evaluation of CD99/Clathrin (A) and CD99/Caveolin-1 (B) colocalizations upon 10, 30 
and 60 minutes of 0662 treatment in U2/CD99wt57. On the right, confocal microscopy analyses 
confirm the results from IF assays depicted on the left.    
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7. CD99 and IGF-1R interaction upon 0662 treatment 
Previously we reported an increase of IGF-1R in ES cell lines both at protein and 
mRNA level following treatments; notably, FACS analysis highlighted a decrease of 
its expression on the cell surface, suggesting that the receptor could possibly undergo 
an internalization process. Based on these results and considering the documented 
mAb-induced internalization of CD99, we explored the hypothesis of an interaction 
between the two receptors, which could likely share the same fate. Once again we 
carried out combined treatments using 0662 and MG132 + lysosome inhibitors for 1 
hour, 3 hours and 6 hours and we evaluated the CD99/IGF-1R co-localization by IF 
assays in U2/CD99wt57: both receptors resulted homogeneously widespread 
throughout the cell surface in the untreated control cell line, while after 1 hour of 
treatment CD99 is visible in the form of aggregates beneath the cell surface, even if 
there is no trace of interaction with IGF-1R; on the contrary, the co-localization is 
evident into the cytoplasm after 3 hours of treatment, and it is still slightly present in 
the last time point (Figure 23). 
     
Figure 23. CD99/IGF-1R double staining upon 1, 3 and 6 hours of 0662 and MG132+lysosome 
inhibitor treatments.  
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To further confirm this result, we performed an immunoprecipitation (IP) anti-IGF-
1R using lysates from 6647 previously treated with 0662 for 2 hours; anti-CD99 
western blot analysis showed a marked interaction between the two molecules 
following treatment, corroborating the initial hypothesis (Figura 24). 
 
   
 
Figure 24. Western blotting α-CD99 showing the CD99/IGF-1R strong interaction after IP α-IGF-
1R on lysates of 6647 previously treated for 2 hours with 0662 mAb.  
 
 
8. IGF-1R is not degraded by 0662 mAb treatments 
Once determined the IGF-1R internalization and its interaction with CD99 upon 
treatments, we then proceeded to investigate the observed process in details. In order 
to prove that the complex IGF-1R/CD99 could be internalized inside the endosomes, 
we performed a triple staining to detect the two receptors and Rab5, an early 
endosome marker involved in the biogenesis of endosomes. Confocal microscopy 
analysis on U2/CD99wt57 mAb-treated for 30, 60 and 90 minutes revealed that not 
only IGF-1R and CD99 formed a complex, confirming previous results, but each of 
them colocalized also with Rab5 (Figure 25).  
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Figure 25. CD99/IGF-1R/Rab5 complex (merge) detected by confocal microscopy analysis in 
U2/CD99wt57 treated for 30, 60 and 90 minutes with 0662 [3 µg/ml]. 
 
The next step has been to evaluate wheter IGF-1R could share the same fate of CD99 
and undergo a lysosome-mediated degradation. We set up the same time-course 
treatment used to investigate the CD99/Lamp-1 co-localization in U2/CD99wt57, 
employing the combination of 0662 and MG132 + lysosome inhibitors, but in this 
case IGF-1R showed a different sorting, since none of the treatments caused the 
interaction with Lamp-1 observed for CD99 (Figure 26).  
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Figure 26. IGF-1R does not undergo lysosome-mediated degradation. Treatments were carried out 
with 0662 [3 µg/ml] and MG132 [100 µM] + lysosome inhibitor [20 µM] (leupeptin + pepstatin).  
 
Conversely, confocal microscopy images depicted in Figure 27 show that IGF-1R is 
recycled on the cell surface, since it was found to colocalize with Rab 11, particularly 
after 60 and 90 minutes of treatment.  
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Figure 27. IGF-1R recycling on the cell surface. 
 
 
9. Ras-MAPK signaling is activated in response to treatment 
Considered the up-regulation of IGF-1R in protein and mRNA, and since it is not 
degraded following its internalization, but recycled on the surface, we investigated 
the modulation of Ras-MAPK pathway, one of the two main pathways associated to 
IGF-1R activation. As shown in Figure 25, 0662 mAb treatments in 6647 and LAP35 
cell lines caused a strong Ras induction detected by western blotting and by IF 
assays, together with ERK phosphorylation and its traslocation to the nucleus. 
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Figure 25. Ras-MAPK up-regulation in ES cells. (A) Western blotting depicting Ras and pERK 
induction following treatments; in the lower panel the cytosol/nucleus separation shows the ERK 
traslocation into the nucleus after its mAb-induced phosphorylation. (B) Ras activation detected in 
6647 by IF assay. 
 
 
A plethora of data in literature point out to a “non conventional” localization of Ras 
proteins; all Ras isoforms, infact, have been found to signal from a variety of 
intracellular membranes, including endosomes (112, 113). For this reason, we 
evaluated an eventual Ras interaction with CD99 upon or concomitantly with its 
induction by 0662 treatment. IF images in Figure 26 prove that the two molecules 
resulted physically linked in U2/CD99wt57 after 1, 3 and 6 hours of mAb exposure; 
this co-localization has been detected also by anti-Ras western blotting after anti-
CD99 immunoprecipitation (IP), as a first instance, and anti-IGF-1R IP as a second 
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instance: both circumstances  supported the supposed interaction (Figura 26). 
 
 
 
 
 
Figure 26. CD99/Ras interaction in ES and osteosarcoma cells.(A) IF images of 0662-treated 
U2/CD99wt57;(B) Anti-Ras western blotting after IP anti-CD99 (right) and IP anti-IGF-1R (left). 
In the first case the IP has been performed using 500 µg of lysates, while in the second case 900 µg 
have been used.  
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10. Cytoplasm vacuolization during 0662 mAb-induced cell 
death: autophagy hypothesis 
Growing evidences demonstrate that the Ras prolonged and strong expression 
promotes cell death in many cellular contexts (93); particularly, Ras seems to be 
involved in autophagic cell death mechanisms (94, 95) and since 0662 mAb-induced 
cell death occurs in a caspase-independent manner, we tried to understand wheter the 
two events were functionally linked in the ES cellular context. Morphological 
analysis by electron microscopy showed an increase in cells with empty vacuoles, 
autophagosomes and less dense cytoplasm upon 0662-mAb treatment (Figure 27), but 
no features typical of apoptosis such as chromatin hyper-condensation, nuclei 
fragmentation, or cytoplasmic shrinkage.  
 
 
   
 
 
Figure 27. Transmission electron 
microscopy of untreated or 0662 
MAb treated 6647 cells and LAP35 
cells at 3000 (top line) and 20000 
(bottom line) fold magnification. In 
particular, autophagosomes are 
visibles as “rosette formations” in 
6647 after 1h of MAb exposure. 
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Normally, upon induction of the autofagic process, LC3-IB is conjugated to the 
highly lipophilic phosphatidylethanolamine (PE) moiety of the autophagosome to 
generate LC3-IIB, which represents the main marker of autophagy; its analysis in ES 
cells treated with 0662-mAb revealed a punctate pattern of LC3-IIB distribution and 
its association with autophagic vacuoles (Figure 28), together with the accumulation 
in LAP35 cells (Figure 28).  
 
              
Figure 28. On the left: western blot analysis of LC3IIB on whole cell extracts from control (-) or 
treated (+) LAP35 is shown; Immunogold anti-LC3 staining of 0662 MAb-treated LAP35 cells at 
20000 fold magnification is depicted on the right.   
 
 
To validate all the evidence pointing to autophagy as the type of caspase-independent 
death caused by 0662 mAb employment, we stably silenced Atg7, an essential 
autophagy gene whose protein partecipates to the formation of LC3-IIB together with 
Atg3 (E2-like conjugating activity) and Atg12-Atg5-Atg16L multimers (E3-like 
ligase activity)(114). Atg7-silenced cells still underwent cell death following CD99 
engagement (Figure 29).   
 53 
 
Figure 29. On the top, western blotting anti-ATG7 showing that the inducible silencing of atg7 in 
6647 and LAP35 cells was successful; on the bottom, cell death evaluation expressed as percentage 
of live (grey) or propidium iodide-positive (light grey) LAP35pLKO SCR, LAP35pLKOshATG7, 
6647pLKO SCR, 6647pLKOshATG7 cells before and after treatment with 0662 mAb. 
 
 
11. Ras has an active role in the observed cell death 
The marked Ras induction and the observation that many vacuoles appeared devoid 
of cytoplasmic components suggested that CD99-mediated cell death might occur 
through hyperstimulation of macropynocitosis, as mentioned in literature for other 
cellular contexts (71). In order to confirm the role of Ras in the observed death we 
established a ES cell line (6647) stably expressing a Ras dominant negative construct, 
HRasN17. This mutant form of Ras, obtained by a substitution of serine 17 with 
aspargine, has a higher affinity for exchange factors than does wild-type Ras but it 
cannot interact with downstream effectors, resulting in the formation of unproductive 
complexes, thereby preventing the activation of endogenous Ras (115). HRasN17 
construct expression in 6647 modified significantly cell viability upon 24 and 48 
hours of 0662 mAb treatments, if compared to parental 6647 cell line, determining a 
reduction in the percentage of cell death (trypan blue positivity) after 24 hours of 
treatment (Figure 30). 
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Figure 30. (A) Western blot analysis of p-ERK expression in lysates from 6647 and 6647HRasN17 
mAb-treated/not treated demonstrating the reliability of the model. (B) MTT cell viability assay of 
6647 and 6647/HRasN17 upon 24 and 48 hours of 0662 mAb exposure. (C) Trypan blue vital 
counts confirming the slight cell death rescue of 6647HRasN17: 20% of 6647 died after treatment, 
while the percentage of dead cells decreased to 7% for 6647HRasN17.  
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12. Mesenchymal stem cells are resistant to 0662 mAb-induced 
cell death 
Since CD99 is broadly expressed at low levels also in normal tissues, to investigate 
the selectivity of therapeutic strategies based on CD99 targeting we evaluated the 
effect of 0662-mAb on human mesenchymal stem cells.  
 
 
Figure 31. FACS analysis of CD99 expression detected in mesenchymal stem cells. 
 
We took advantage of several human mesenchymal cell lines of distinct origins 
(CORION-3386, HSSC 195, HSSC 196, DP15, HSSC 244 AND HSSC 249) 
characterized by different levels of CD99 expression (Figure 31) and we tested them 
for annexin V/PI positivity following 0662 treatments, finding that not even those 
with a higher expression of the receptor (HSSC 244 and HSSC 249) were mAb-
sensitive (Figure 32), since they did not displayed neither annexin V-PI staining  nor 
activation of p-ser15-p53. On the contrary, CD99 triggering was still able to induce 
mild Ras activation and p21 induction (Figure 32). 
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Figure 32. (A)Evaluation of Annexin V/PI positivity upon MAb 0662 treatment on 6647 and on 
hMSCs from different origins. (B) Western blotting analysis of Ras, p21, phospho-serine15-p53, 
and total p53 before (-) and after (+) treatment with 3µg/ml 0662 MAb on 6647 and two different 
hMSCs.  
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13. EWS/FLI1 favors the delivering of the CD99-induced cell 
death message 
Based on the results obtained with human mesenchymal stem cells, we explored 
whether the CD99-induced cell death message requires an aberrant oncogenetic-
driven cellular context. Considering the pivotal oncogenetic role of EWS/FLI1 in ES 
cells, we took advantage of a murine mesenchymal model, namely C3H10T1/2 EF 
CD99, transfected both with EWS/FLI1 and CD99 as reported in literature (40), 
demonstrating that treatment with 0662 mAb is sufficient to trigger cell death and to 
induce phosphorylation of serine 15 of p53 within 1 hour, together with a stronger 
Ras upregulation compared to that observed in HSSC 244 and HSSC 249 (Figure 33). 
                    
                                           
Conversely, when we silenced EWS/FLI1 we obtained a partial but significant 
reversal of the annexin-V positive cells after CD99 engagement (Figure 34). These 
Figure 33. (A) FACS analysis of CD99 expression in 6647 (left) and in C3H10T1/2 EF CD99 
(right). (B) Cell death evaluation by AnnexinV/PI binding in 6647 and in C3H10T1/2 EF CD99 
with and without 0662 treatment (1h/4h). (C) Western blot analysis of p53 phosphorylation, p53 
whole lysates, p21 and Ras upon 0662 mAb exposure (1h/4h). (D) IF assay showing Ras 
induction in C3H10T1/2 EF CD99 mAb-treated. 
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data were repeated in LAP35 (Figure 34) and, overall, they suggest that 0662 mAb 
preferentially delivers a massive cell death message in an aberrant cellular context in 
which both Ras upregulation and p53 reactivation are requested. 
 
        
         
Figure 34. (A) Upper panel: histogram depicting Annexin V/PI positivity upon 0662 treatment on 
C3H10T1/2 EF CD99, and western blotting anti-EWS/FLI1 demostrating the successful silencing. 
(B) Upper panel: evaluation of live, apoptotic and necrotic cells by annexin V/PI binding on LAP35 
and western blot analysis showing the reliability of the silencing. In both lower panels values from 
respective histograms are reported.  
 
 
 
B 
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DISCUSSION 
 
Ewing Sarcoma is the second most common bone tumor after osteosarcoma; it is 
extremely rare and aggressive and characterized by a simple cariotype with a specific 
chromosomal rearrangement (the fusion of EWSR1 gene to a member of ETS family 
of trascription factors, most frequently FLI1), which leads to the formation of an 
aberrant fusion product responsible not only for the cell trasformation itself but also 
for the manteinance of the disease (8, 9). Nevertheless, EWS/FLI1, despite its pivotal 
role as a driver of the malignancy, requires a permissive cellular background that 
includes an intact IGF pathway and the presence of CD99 molecule, essential 
elements without which it is not able to trasform cells (40, 116). EWS/FLI1 promotes 
an high expression of CD99 in many cellular types (37, 39, 117), the latter a 
membrane glycoprotein involved in cellular adesion mechanisms, apoptosis, T-cell 
and timocytes differentiation (20, 29, 118), monocytes extravasation (119) and 
intracellular adesion between lymphocytes and endothelial cells (120). 
Because of its high expression on the Ewing cell surface, CD99 is considered to be a 
good marker for the diagnosis of the neoplasia (17, 23). Moreover, it was 
demonstrated the oncogenetic role of CD99 in ES cells, since it inhibits neural 
differentiation in this context (40). Molecular targeting by use of monoclonal 
antibodies has emerged as a new therapeutic strategy in many disorders. The CD99 is 
considered a selective and effective target for therapy of ES because it promotes 
homotypic aggregation and cancer cell death when triggered by specific 
antibodies(43, 44, 121). Although activation of the RAS/MAPK pathway in cancer 
cells is usually associated with tumor cell proliferation, recent studies support a 
paradoxical role in the initiation of cell death as well as in cell differentiation and 
growth arrest in specific cellular contexts, including ES (40, 71, 89, 94, 95). The 
tumor suppressor protein p53 is rarely mutated in ES (less than 10%) if compared to 
other malignancies, but is functionally inactivated by several mechanisms including 
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overexpression of MDM2(108, 122, 123). Both p53 and IGF-IR signaling are 
modulated as a consequence of MDM2 inactivation (109, 124). MDM2 is an E3 
ubiquitin ligase that antagonizes the tumor suppressor p53 by inhibiting its ability to 
transactivate target genes or by promoting its degradation or nuclear export. Besides, 
MDM2 serves as a ubiquitin ligase for the IGF-1R, thereby causing its degradation 
by the proteasome (109-111). Preliminary data report a marked and rapid decrease of 
MDM2 protein levels following CD99 triggering; this downmodulation is both dose- 
and time-dependent and leads to p53 reactivation, thus contributing to CD99-induced 
caspase-independent cell death. As a consequence of MDM2 ubiquitination and 
proteasome-degradation, IGF-1R is upregulated following 0662 mAb treatments, 
leading, as a second step, to a decrease of IGF-1R levels on the cell surface because 
of the receptor internalization. At the same time, CD99 also undergoes an 
internalization process, both in a clathrin- and caveolin-1-dependent fashion, leading 
ultimately to a degradation of the receptor by lysosomes, predominantly; the 
degradation process is further validated by the lack of recycling of CD99 on the cell 
surface, since it failes to colocalize with Rab11, a late endosome marker involved in 
recycling processes. On the contrary, the demonstrated interaction with Rab4, an 
early endosome marker, proves that the entire mechanism takes place through the 
formation of endosomes, endocytic vescicles basically involved in the uptake of 
membrane proteins, lipids, extracellular ligands and soluble molecules, such as 
nutrients, from the cell surface into the cell interior. 
CD99 and IGF-1R not only are internalized into the cell upon 0662 mAb 
employment, but they interact during the process; IF images and IP assays show that 
they are phisically linked at the beginning of the process, forming a complex within 
endosomes, but later their fates are different: while CD99 undergoes a lysosome-
mediated degradation, IGF-1R does not colocalize with Lamp-1, the main lysosome 
marker; this different sorting leads IGF-1R to a recycling on the cell surface again, 
keeping it active and able to emit signals. In this context we find Ras-MAPK pathway 
significantly upregulated; as mentioned in literature, RAS activation can induce non-
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apoptotic cell death in neuroblastoma and in glioblastoma cells (71, 95). While in 
neuroblastoma cell death occurs through a classical autophagic process(95), in 
glioblastoma RAS acts through Rac-dependent pathways eventually hyper-
stimulating macropinocytosis (71). Since CD99-induced cell death is a caspase-
independent mechanism (44), and electron microscopy images demonstrated that 
CD99 engagement induces a massive cytoplasm vacuolization, we investigated the 
role of autophagy in the observed mAb-induced death. Autophagic processes can 
either enhance cell survival in response to nutrient deprivation, organelle damage or 
stress, or result in cell death when sustained for a long time (68). Autophagy-
associated cell death occurs without DNA fragmentation, nuclear collapse or 
cytoplasmic shrinkage and death is the result of excessive engulfment and subsequent 
digestion of proteins and organelles in response to cellular stresses (57). During this 
process, organelles and proteins are sequestered in a double-membrane vesicle called 
autophagosome. The formation of autophagosomes involves several specific proteins 
such as autophagy-related gene (Atg) 6 (Beclin-1) (125), the Atg12-Atg5-Atg16 
complex and the ubiquitin-like protein Atg8 (known as LC3 in mammalian cells), 
which is activated by the Atg7 protein (125). The molecular marker of autophagy 
LC3, which is normally expressed in a diffuse pattern in healthy cells, was associated 
with vesicle membranes, and processed into its active LC3-IIB form. Since silencing 
of Atg7, a crucial component of the autophagic machinery, was unable to rescue 
CD99-induced cell death, we concluded that ES cell death does not occur through 
autophagy as in neuroblastoma, but it happens with macropinocytosis followed by 
necrosis as in glioblastoma. We propose that RAS induction might contribute to the 
delivery of CD99-dependent death signals. Despite its well described role in 
tumorigenesis as a pro-survival/proliferation factor, increasing evidence indicates that 
RAS is able to switch cell fate toward death in specific cellular contexts, such as in 
normal primary cells (89) and in cancer cells under certain conditions (93). Indeed, 
we confirmed its involvement in favoring cell death by the employment of ES cell 
line expressing a Ras dominant negative construct, realizing a partial rescue from 
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death following 0662 treatments, if compared to that observed in parental cell line. 
Moreover, activation of RAS is required for mortality when cells are exposed to other 
inducers of cell death (126, 127). Accordingly, hMSCs expressing high levels of 
CD99 are insensitive to the 0662 mAb despite RAS induction, because no p53 
reactivation occurs in these normal primary cells. RAS effects vary greatly in 
different cellular contexts and in relation to its expression level and cellular genetic 
context, switching from inducer of transformation in immortalized fibroblasts to 
driver of cell death in cancer cells or differentiation and growth arrest in neuronal, 
adipocytic, or myeloid cells (89). In this study we propose that in the non-trasformed 
context of hMSCs the modest CD99-induced RAS upregulation is insufficient to 
commit cell towards cell death in absence of p53 cooperation. On the contrary, in 
cancer cells RAS continues to promote tumor growth, leaving them vulnerable to the 
effects of p53 reactivation and to the derived signaling conflict. We also determined 
that the presence of EWS/FLI1, which requires p53 inactivation for its oncogenic 
activity (128), sensitizes tumor cells to 0662 mAb; infact, treatments carried out in 
the murine mesenchymal cell line double-transfected with CD99 and EWS/FLI1 
(C3H10T1/2 EF CD99) resulted in a significant increase of cell death, with a 
concomitant phosphorylation of p53 and an induction of Ras stronger than that 
detected in hMSCs. Upon CD99 engagement and subsequent p53 reactivation, 
EWS/FLI1 activity becomes insufficient to sustain transformed ES cells. In this 
context, aberrant RAS up-regulation might deliver a death  rather than a pro-survival 
signal. Concluding, we can depict the following scenario: CD99 triggering induces a 
rapid MDM2 ubiquitination and degradation. On one side, the abrogation of MDM2 
reactivates p53 functions in ES cells, while on the other hand, the reported MDM2 
downregulation causes the IGF-1R induction and its subsequent internalization inside 
endosomes with CD99 itself. Once internalized, IGF-1R is still able to signal and 
promotes a sustained activation of RAS, which may switch its functions from 
survival to cell death, in a context already pre-ordered by p53 activation. Unlike in 
healthy cells, engagement of CD99 in a EWS/FLI1-driven oncogenetic context 
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creates a synergy between RAS upregulation and p53 activation in ES cells, leading 
to cell death and thus allowing higher therapeutic selectivity.  
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